ABSI
NASDAQAbsci Corporation
Website
News25/Ratings12
News · 26 weeks54-79%
2025-10-262026-04-19
Mix3890d
- Insider20(53%)
- Other8(21%)
- SEC Filings6(16%)
- Earnings3(8%)
- Leadership1(3%)
Latest news
25 items- PRAbsci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the first quarter 2026 after market close on Thursday, May 7, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The
- SECSEC Form DEF 14A filed by Absci CorporationDEF 14A - Absci Corp (0001672688) (Filer)
- SECSEC Form DEFA14A filed by Absci CorporationDEFA14A - Absci Corp (0001672688) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Absci CorporationSCHEDULE 13D/A - Absci Corp (0001672688) (Subject)
- PRAbsci to Participate in the 25th Annual Needham Virtual Healthcare ConferenceVANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the upcoming 25th Annual Needham Virtual Healthcare Conference. Absci management is scheduled to participate in a fireside chat on Thursday, April 16th at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company's investor relations website at: investors.absci.com. About Absci Absci is advancing the future of drug discovery with generative design to create better bio
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Absci CorporationSCHEDULE 13D/A - Absci Corp (0001672688) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Absci CorporationSCHEDULE 13G/A - Absci Corp (0001672688) (Subject)
- SECSEC Form S-8 filed by Absci CorporationS-8 - Absci Corp (0001672688) (Filer)
- SECSEC Form 10-K filed by Absci Corporation10-K - Absci Corp (0001672688) (Filer)
- SECAbsci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Absci Corp (0001672688) (Filer)
- PRAbsci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating ResultsSuccessfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported
- PRAbsci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo ClinicVANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, announced the launch of an endometriosis advisory board for its ABS-201 program in clinical development for endometriosis. The Advisory Board consists of endometriosis and clinical development experts with backgrounds from renowned institutions including the Yale University School of Medicine, Duke University School of Medicine, UCSF, and the Mayo Clinic. Endometriosis is a chronic, painful inflammatory disease defined by endometrium-like lesions found outside the uterus affecting an
- INSIDERAmendment: Chief Legal Officer Walker Shelby J. was granted 90,300 shares and covered exercise/tax liability with 9,825 shares, increasing direct ownership by 136% to 139,775 units (SEC Form 4)4/A - Absci Corp (0001672688) (Issuer)
- INSIDERAmendment: CFO / CBO Jonasson Zachariah was granted 135,400 shares and covered exercise/tax liability with 10,848 shares, increasing direct ownership by 33% to 499,783 units (SEC Form 4)4/A - Absci Corp (0001672688) (Issuer)
- INSIDERAmendment: SVP, CAO Bedrick Todd was granted 49,600 shares and covered exercise/tax liability with 5,282 shares, increasing direct ownership by 26% to 216,942 units (SEC Form 4)4/A - Absci Corp (0001672688) (Issuer)
- INSIDERAmendment: Chief Executive Officer Mcclain Sean was granted 406,200 shares and covered exercise/tax liability with 25,316 shares, increasing direct ownership by 5% to 8,715,451 units (SEC Form 4)4/A - Absci Corp (0001672688) (Issuer)
- INSIDERChief Innovation Officer Busch Andreas bought $229,000 worth of shares (100,000 units at $2.29), increasing direct ownership by 31% to 421,446 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- SECAbsci Corporation filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Absci Corp (0001672688) (Filer)
- PRAbsci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Absci's Chief Medical Officer. The inducement grant was previously approved by the Compensation Committee of Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the "Inducement Plan"), and is being made as an inducement material to the new employee's acceptance o
- INSIDERDirector Pangalos Menelas N was granted 5,800 shares, increasing direct ownership by 3% to 194,855 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERChief Legal Officer Walker Shelby J. covered exercise/tax liability with 9,825 shares and was granted 90,300 shares, increasing direct ownership by 136% to 139,775 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERChief Executive Officer Mcclain Sean was granted 406,200 shares and covered exercise/tax liability with 25,316 shares, increasing direct ownership by 5% to 8,715,451 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERSVP, CAO Bedrick Todd was granted 49,600 shares and covered exercise/tax liability with 5,282 shares, increasing direct ownership by 26% to 216,942 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERCFO / CBO Jonasson Zachariah was granted 135,400 shares and covered exercise/tax liability with 10,848 shares, increasing direct ownership by 33% to 499,783 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERChief Innovation Officer Busch Andreas covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 0.39% to 321,446 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)